Last reviewed · How we verify
NCT04373629
Perceptual Abnormalities and Their Malleability in BDD
NA trial testing attentional modulation in Body Dysmorphic Disorder in 146 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 146 |
| Start date | 1 December 2020 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- attentional modulation
- perceptual modulation
- naturalistic viewing
Conditions studied
- Body Dysmorphic Disorder — all drugs for Body Dysmorphic Disorder →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
Adults 18 to 40, any sex, with Body Dysmorphic Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at risk for relapse. Results from this study will provide a comprehensive mechanistic model of brain, behavioral, and emotional contributors to abnormal perceptual processing, as well as how malleable it is with visual modulation techniques. This will lay the groundwork for next-step translational perceptual retraining approaches.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04373629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Body Dysmorphic Disorder
Currently open trials in the same condition.
- NCT07036744 — When The Mirror Is Wrong · NA · recruiting
- NCT06678295 — Individual Factors of CBT Underlying Success · NA · recruiting
- NCT06781853 — CBT for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial · NA · active not recruiting
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04373629 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 14 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04373629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing